Feb 8: Mumbai-based pharma major Lupin Ltd on Thursday announced the launch of its Clonidine Hydrochloride extended-release tablets, 0.1mg, having received an approval from the United States Food and Drug Administration (USFDA) earlier.
“Lupin’s Clonidine Hydrochloride ER tablets is the generic equivalent of Concordia International Corp’s Kapvay tablets. It is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) as monotherapy or as adjunctive therapy to stimulant medications,” the company said in a statement.
According to IQVIA MAT December 2017 data, Kapvay tablets had annual sales of approximately $66 million in the US.
Lupin shares were trading at Rs 812.80, up 0.60% from the previous closing of Rs 807.95, on BSE at 2.59 pm today.